Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide with Chemoradiotherapy in Stage III NSCLC
NCT00004859Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2000
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of thalidomide in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Jan 2000; status: terminated.
02
Drugs
thalidomide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00004859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004859.